AMT Successful in Preclinical Treatment of DMD
"We are proud to establish proof of concept with our gene therapy for Duchenne muscular dystrophy, as it is an important new step in developing a treatment for this progressive and devastating disease," said Jörn Aldag, Chief Executive Officer of AMT. "In particular, our positive results in the heart and respiratory muscles bring hope that we might be able to prevent the fatal outcome of this disease in the future, potentially through a long-term remedy with a single treatment."
Topics
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.